Patents by Inventor Jérôme COURCAMBECK

Jérôme COURCAMBECK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11261189
    Abstract: 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments are disclosed. The compounds are useful as a medicament in treating and/or decreasing the severity and/or progression and/or preventing fibrosis and/or related diseases, or for use as a medicament in treating, decreasing the severity and/or progression of and/or preventing autophagy and/or related diseases, for inhibiting autophagy flux, and for inhibiting cathepsins B (CTSB), L (CTSL) and/or D (CTSD) and/or related diseases.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: March 1, 2022
    Assignee: GENOSCIENCE PHARMA
    Inventors: Philippe Halfon, Firas Bassissi, Sonia Brun, Jérôme Courcambeck, Madani Rachid
  • Patent number: 10722505
    Abstract: The present invention relates to novel 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments. The active compounds of the present invention are useful for the treatment and prevention of proliferative neoplastic and non-neoplastic diseases.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: July 28, 2020
    Assignee: GENOSCIENCE PHARMA
    Inventors: Firas Bassissi, Antoine Beret, Sonia Brun, Jérôme Courcambeck, Clarisse Dubray, Gregory Nicolas, Philippe Halfon
  • Publication number: 20200079781
    Abstract: 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments are disclosed. The compounds are useful as a medicament in treating and/or decreasing the severity and/or progression and/or preventing fibrosis and/or related diseases, or for use as a medicament in treating, decreasing the severity and/or progression of and/or preventing autophagy and/or related diseases, for inhibiting autophagy flux, and for inhibiting cathepsins B (CTSB), L (CTSL) and/or D (CTSD) and/or related diseases.
    Type: Application
    Filed: August 1, 2019
    Publication date: March 12, 2020
    Inventors: Philippe Halfon, Firas Bassissi, Sonia Brun, Jérôme Courcambeck, Madani Rachid
  • Patent number: 10577362
    Abstract: This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein which exhibit strong inhibition effects on various cancer cell lines. The compounds disclosed herein are useful for the treatment of proliferative diseases, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing compounds of Formula I and at least one carrier, diluent or excipient and optionally one or more additional therapeutically active agents, including anticancer agents. This application also discloses methods for treating a proliferative disease, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: March 3, 2020
    Assignee: GENOSCIENCE PHARMA
    Inventors: Sonia Brun, Antoine Beret, Firas Bassissi, Philippe Halfon, Jérôme Courcambeck
  • Publication number: 20190314359
    Abstract: The present invention relates to novel 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments. The active compounds of the present invention are useful for the treatment and prevention of proliferative neoplastic and non-neoplastic diseases.
    Type: Application
    Filed: October 26, 2015
    Publication date: October 17, 2019
    Inventors: Firas BASSISSI, Antoine BERET, Sonia BRUN, Jérôme COURCAMBECK, Clarisse DUBRAY, Gregory NICOLAS, Philippe HALFON
  • Publication number: 20190144437
    Abstract: This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein which exhibit strong inhibition effects on various cancer cell lines. The compounds disclosed herein are useful for the treatment of proliferative diseases, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing compounds of Formula I and at least one carrier, diluent or excipient and optionally one or more additional therapeutically active agents, including anticancer agents. This application also discloses methods for treating a proliferative disease, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis.
    Type: Application
    Filed: May 4, 2017
    Publication date: May 16, 2019
    Applicant: GENOSCIENCE PHARMA
    Inventors: Sonia BRUN, Antoine BERET, Firas BASSISSI, Philippe HALFON, Jérôme COURCAMBECK
  • Patent number: 10179770
    Abstract: The invention provides quinoline derivatives, their manufacture, pharmaceutical compositions containing them, and their use as medicaments. The active compounds of the present invention are useful for the treatment of proliferative neoplastic and non-neoplastic diseases.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 15, 2019
    Assignee: GENOSCIENCE PHARMA
    Inventors: Jerome Courcambeck, Philippe Halfon, Firas Bassissi, Sonia Brun, Gregory Nicolas, Antoine Beret, Serge Petit, Claire Camus, Jean Pierre Nallet
  • Publication number: 20160280653
    Abstract: The invention provides quinoline derivatives, their manufacture, pharmaceutical compositions containing them, and their use as medicaments. The active compounds of the present invention are useful for the treatment of proliferative neoplastic and non-neoplastic diseases.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 29, 2016
    Inventors: Jerome COURCAMBECK, Philippe HALFON, Firas BASSISSI, Sonia BRUN, Gregory NICOLAS, Antoine BERET, Serge PETIT, Claire CAMUS, Jean Pierre NALLET
  • Patent number: 8729014
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HCV in human patients or other animal hosts.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: May 20, 2014
    Assignees: RFS Pharma, LLC, Genoscience
    Inventors: Jerome Courcambeck, Philippe Halfon, Mourad Bouzidi, Steven J. Coats, Richard Anthony Whitaker
  • Publication number: 20120129765
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HCV in human patients or other animal hosts.
    Type: Application
    Filed: October 28, 2011
    Publication date: May 24, 2012
    Applicants: GENOSCIENCE, RFS Pharma, LLC
    Inventors: Jerome Courcambeck, Philippe Halfon, Mourad Bouzidi, Steven J. Coats, Richard Anthony Whitaker
  • Publication number: 20060142204
    Abstract: The present invention relates to novel hepatitis C virus (“HCV”) protease inhibitors or other flavivirus protease inhibitors having the general structure (I) or (II), pharmaceutical compositions containing one or more such inhibitors, methods for preparing such inhibitors, uses of these compounds to treat hepatitis C and related disorders together with their use for their activity towards NS3 serine protease, intermediary compounds for the method of preparation of said compounds and screening methods. The invention specifically discloses novel chemical compounds as inhibitors of the HCV serine protease.
    Type: Application
    Filed: October 9, 2003
    Publication date: June 29, 2006
    Applicant: GENOSCIENCE
    Inventors: Philippe Halfon, Chalom Sayada, Jean-Marc Feryn, Regis Perbost, Frederic Garzino, Michel Camplo, Jerome Courcambeck, Gerard Pepe